Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Resilience acquires AstraZeneca’s Ohio plant

by Rick Mullin
December 1, 2022 | A version of this story appeared in Volume 100, Issue 43

 

National Resilience, a biomanufacturing services firm, will acquire an AstraZeneca dosage-form drug plant in West Chester, Ohio. The deal accompanies a multiyear agreement under which Resilience will make medicines for the drug firm at the 54,000 m2 facility. Since launching 2 years ago with $800 million in funding, Resilience has amassed several drug services operations, including Ology Bioservices, a maker of active ingredients for biologic drugs, in Alachua, Florida.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.